Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 1, 2012, Pages 72-78

  Raffa, Sebastián ^a   Reverter, Juan Carlos ^a   Seijo, Susana ^a   Tassies, Dolors ^a   Abraldes, Juan G ^a   Bosch, Jaume ^a   García Pagán, Juan Carlos ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

CLT; Hemostatic Disorders; Portal Hypertension; Ristocetin Cofactor; VWF

Indexed keywords

ANTIPLASMIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; FIBRINOGEN; PLASMIN; PROTEIN C; PROTEIN S; PROTHROMBIN; RISTOCETIN; RISTOCETIN COFACTOR; THROMBIN; THROMBOMODULIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; IDIOPATHIC DISEASE; MALE; NONCIRRHOTIC PORTAL VEIN THROMBOSIS; PARTIAL THROMBOPLASTIN TIME; PORTAL VEIN THROMBOSIS; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBOPHILIA;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION FACTORS; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PORTAL VEIN; PROTHROMBIN TIME; THROMBOPHILIA; THROMBOSIS; YOUNG ADULT;

EID: 83755224861     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.09.010     Document Type: Article

References (39)

1. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005, 43:167-176.
2. Seijo-Ríos S., García-Pagán J.C. [Portal vein thrombosis]. Gastroenterol Hepatol 2010, 33:179-190.
3. Garcia-Pagán J.C., Hernández-Guerra M., Bosch J. Extrahepatic portal vein thrombosis. Semin Liver Dis 2008, 28:282-292.
4. Sarin S.K., Agarwal S.R. Extrahepatic portal vein obstruction. Semin Liver Dis 2002, 22:43-58.
5. Condat B., Pessione F., Hillaire S., et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001, 120:490-497.
6. Amitrano L., Guardascione M.A., Scaglione M., et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 2007, 102:2464-2470.
7. Robson S.C., Kahn D., Kruskal J., et al. Disordered hemostasis in extrahepatic portal hypertension. Hepatology 1993, 18:853-857.
8. Bajaj J.S., Bhattacharjee J., Sarin S.K. Coagulation profile and platelet function in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis. J Gastroenterol Hepatol 2001, 16:641-646.
9. Chiu B., Melin-Aldana H., Superina R.A. Human extrahepatic portal vein obstruction correlates with decreased factor VII and protein C transcription but increased hepatocyte proliferation. J Pediatr Surg 2007, 42:1768-1771.
10. Dubuisson C., Boyer-Neumann C., Wolf M., et al. Protein C, protein S and antithrombin III in children with portal vein obstruction. J Hepatol 1997, 27:132-135.
11. Fisher N.C., Wilde J.T., Roper J., et al. Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon?. Gut 2000, 46:534-539.
12. Mack C.L., Superina R.A., Whitington P.F. Surgical restoration of portal flow corrects procoagulant and anticoagulant deficiencies associated with extrahepatic portal vein thrombosis. J Pediatr 2003, 142:197-199.
13. Tripodi A., Mannucci P.M. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007, 46:727-733.
14. Berntorp E., Salvagno G.L. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 2008, 34:670-682.
15. Perelló A., García-Pagán J.C., Gilabert R., et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002, 35:132-139.
16. Turnes J., García-Pagán J.C., González M., et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol 2008, 6:1412-1417.
17. Pabinger I., Allaart C.F., Hermans J., et al. Hereditary protein C-deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC Subcommittee on protein C and protein S. Protein C Transmitter Study Group. Thromb Haemost 1992, 68:470-474.
18. Janssen H.L., Meinardi J.R., Vleggaar F.P., et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000, 96:2364-2368.
19. Hemker H.C., Giesen P., Al Dieri R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemos Thromb 2003, 33:4-15.
20. Tripodi A., Primignani M., Chantarangkul V., et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009, 137:2105-2111.
21. Tripodi A., Primignani M., Lemma L., et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010, 52:249-255.
22. Caldwell S.H., Hoffman M., Lisman T., et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006, 44:1039-1046.
23. Kujovich J.L. Hemostatic defects in end stage liver disease. Crit Care Clin 2005, 21:563-587.
24. Prasad C.V., Kaur U., Marwaha N., et al. Hemostatic alterations in non-cirrhotic portal fibrosis, extrahepatic portal venous obstruction and Budd-Chiari syndrome. Indian J Gastroenterol 1990, 9:57-60.
25. Denis C.V., Christophe O.D., Oortwijn B.D., et al. Clearance of von Willebrand factor. Thromb Haemost 2008, 99:271-278.
26. van Schooten C.J., Shahbazi S., Groot E., et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008, 112:1704-1712.
27. Uemura M., Fujimura Y., Matsumoto M., et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008, 99:1019-1029.
28. Esmon C.T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989, 264:4743-4746.
29. Tripodi A., Mannucci P.M. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem 1996, 42:664-669.
30. Ay C., Vormittag R., Dunkler D., et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009, 27:4124-4129.
31. Verhovsek M., Douketis J.D., Yi Q., et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008, 149:481-490. W94.
32. Levi M., Keller T.T., van Gorp E., et al. Infection and inflammation and the coagulation system. Cardiovasc Res 2003, 60:26-39.
33. Vallely M.P., Bannon P.G., Bayfield M.S., et al. Quantitative and temporal differences in coagulation, fibrinolysis and platelet activation after on-pump and off-pump coronary artery bypass surgery. Heart Lung Circ 2009, 18:123-130.
34. Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009, 373:155-166.
35. Bruinstroop E., Klok F.A., van de Ree M.A., et al. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 2009, 7:611-618.
36. Hrometz S.L., Edelmann S.E., McCune D.F., et al. Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction. J Pharmacol Exp Ther 1999, 290:452-463.
37. Curnow J.L., Morel-Kopp M.C., Roddie C., et al. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost 2007, 5:528-534.
38. He S., Antovic A., Blombäck M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb Res 2001, 103:355-361.
39. Lisman T., Leebeek F.W., Mosnier L.O., et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001, 121:131-139.